Migraine Drugs Market Overview

According to Market Research Future (MRFR), the global migraine drugs market is poised to create a valuation of USD 6.5 BN by, registering 3.65% CAGR during the assessment period (2022 – 2030). Despite the recent increase in drug discoveries, there are vast numbers of cases unmet needs, which foster the growth of the market, driving investments in drug developments. Moreover, heady lifestyles accelerate market growth, increasing occurrences of the condition.

Migraine is a disorder leading to extruding pain, sleep-less night, and various health complications. Recently, the US FDA has been approving considerable numbers of drugs aiming to prevent and make migraine occurrences lesser. Despite the recent advances in drug discoveries, there are vast numbers of cases unmet needs, which foster the growth of the market, driving investments in drug developments. Also, the US FDA has been approving considerable numbers of drugs aiming to prevent and make migraine occurrences lesser. As a result, the global Migraine Drugs Market is rising pervasively. Increasing prevalence of the condition is a major driving force behind the growth of the market. Besides, the availability of novel medicines therapies to treat symptoms of the condition, impact the growth of the market positively. Due to the availability of many breakthrough drugs, the market appears well-developed.

Migraine is an episodic disorder leading to severe headache, sleep-less night, and various health complications. It may be accompanied by symptoms such as nausea and light sensitivity, contributing to significant morbidity. Acute migraine treatment has historically consisted of analgesics initiated early in onset. Over recent years the prevalence of migraine is rising uncontrollably. Fortunately, there are many drugs available to treat the condition. Migraine is a common neurovascular sickness that is characterized by tender headaches and is commonly associated with other neurological indications, such as nausea, vomiting, and painful sensitivity to lights and sounds. Migraine is more common in women than men, majorly due to the fluctuations in the hormone levels.  Approximately 12% of the US population suffered from migraine headaches in 2018. The treatment of migraine headaches is eased by the administration of preventive medications, to avoid migraine attacks and abortive medications to relieve strong and periodic pain.

Migraine Drugs Market Segmentation

• The MRFR report provides an all-inclusive segmental analysis of the migraine drugs market on the basis of drug class, treatment, end user, and type. 

• Based on type, the migraine drugs market is segmented into chronic and episodic migraine. Of these, the episodic migraine will have maximum share in the market over the forecast period.

• Based on treatment, the migraine drugs market is segmented into neuromodulation, preventive, acute, and others. Of these, the acute segment will command the largest share in the market over the forecast period owing to its high prevalence and availability of several drugs to treat acute migraines.

• Based on drug class, the migraine drugs market is segmented into triptans, anticonvulsants, tricyclics, angiotensin blockers, beta-blockers, and others. Of these, the triptans segment will lead the market over the forecast period for its high efficacy.

• Based on end user, the migraine drugs market is segmented into research and academic institutes, hospitals and clinics, and others. Of these, hospitals and clinics will dominate the market over the forecast period for being primary treatment centers for patients.

Migraine Drugs Market Regional Analysis

North America is projected to continue to lead the global migraine drug market. The significant share of the market attributes to favorable reimbursement scenarios and high healthcare expenditures. Also, a wide uptake of new technologies for the formulations of new migraine drugs acts as a key driving force for the growth of the regional market. US is the largest market for migraine drugs in North America.

Europe stands second in the global migraine drugs market. Factors such as the increasing prevalence of the condition drive the growth of the market, creating a huge patient pool. Besides, the resurging economy in the region pushes the growth of the regional market, availing many novel treatments and drugs. The European migraine drugs market is expected to grow at a considerable CAGR during the review period.

The migraine drugs market in the Asia Pacific region is estimated to grow rapidly over the assessment period. The market is predominantly driven by China and India, owing to the vast population and the availability of cost-competitive therapeutics. Moreover, the proliferating healthcare sector, coupled with the large unmet needs in the region, would provide impetus to the regional market growth over the forecast period.

Migraine Drugs Market Players

• Allergan Plc (Ireland)
• Alder Biopharmaceuticals Inc. (US)
• Pfizer Inc. (US)
• GlaxoSmithKline Plc (UK)
• Merck Co. Inc. (US)
• Teva Pharmaceutical Industries Ltd (Israel)
• AstraZeneca PLC (UK)
• Johnson Johnson Services Inc. (US)
• Amgen Inc. (US)
• Eli Lilly and Company

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/migraine-drugs-market-8379

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com